Veru (VERU) Change In Inventory : $0.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Veru Change In Inventory?

Veru's change in inventory for the quarter that ended in Dec. 2023 was $-0.20 Mil. It means Veru's inventory increased by $0.20 Mil from Sep. 2023 to Dec. 2023 .

Veru's change in inventory for the fiscal year that ended in Sep. 2023 was $0.65 Mil. It means Veru's inventory declined by $0.65 Mil from Sep. 2022 to Sep. 2023 .

Veru's Total Inventories for the quarter that ended in Dec. 2023 was $6.91 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Veru's Days Inventory for the quarter that ended in Dec. 2023 was 626.55.

Inventory Turnover measures how fast the company turns over its inventory within a year. Veru's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.15.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Veru's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 3.18.

Veru Change In Inventory Historical Data

The historical data trend for Veru's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Change In Inventory Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Inventory

Get a 7-Day Free Trial

-1.45

-3.30

0.55

-3.13

0.65

Veru Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-0.12	0.88	0.08	-0.20	-0.20

Veru Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.56 Mil.

Veru (NAS:VERU) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Veru's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	6.8045	/	0.991	*	365 / 4
	=	626.55

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Veru's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0.991	/	6.8045
	=	0.15

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Veru's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	6.8045	/	2.141
	=	3.18

Veru Change In Inventory Related Terms

Thank you for viewing the detailed overview of Veru's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (VERU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Executives

Mario Eisenberger	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch	director, 10 percent owner	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun	director	48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner	director, 10 percent owner, officer: President and CEO	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco	officer: VP and CFO	515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro	director	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr	officer: CEO of FHC Division	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz	director	2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines	officer: CFO and COO	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune	director	THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish	director, officer: Chairman/Chief Exec. Officer